ASPIRIN AND DIPYRIDAMOLE

Post-LOE

aspirin and extended - release dipyridamole

Pfizer
ANDAORALCAPSULE, EXTENDED RELEASE
Approved
Jan 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (3)

stroke in patientscompleted ischemic stroke due to thrombosiscompleted ischemic stroke due to thrombosis ()
Company
Pfizer
Pfizer
NEW YORK, NY
589 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.